LABORATORY RESEARCH Targeting Prostate Cancer Cell Lines with Polo-Like Kinase 1 Inhibitors as a Single Agent and in Combination with Histone Deacetylase Inhibitors Scientists studied the effect of polo-like kinase 1 inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase inhibitors valproic acid and vorinostat. [FASEB J] Abstract Hypoxia Enhances the Expression of Prostate-Specific Antigen by Modifying the Quantity and Catalytic Activity of Jumonji C Domain-Containing Histone Demethylases Scientists showed that pathological hypoxia increased the expression of androgen receptor target genes such as prostate-specific antigen and kallikrein-related peptidase 2 in LNCaP human prostate cancer cells by modifying the quantity and activity of related Jumonji C domain-containing histone demethylases. [Carcinogenesis] Abstract Peroxiredoxin-3 Is Overexpressed in Prostate Cancer and Promotes Cancer Cell Survival by Protecting Cells from Oxidative Stress Peroxiredoxin-3 (PRDX-3) is upregulated in a number of endocrine-regulated tumors; in particular in prostate cancer and prostatic intraepithelial neoplasia. Although the majority of PRDX-3 is localised to the mitochondria, researchers confirmed that PRDX-3 at the cell membrane is androgen regulated. [Brit J Cancer] Abstract Characterizations of Human Prostate Stem Cells Reveal Deficiency in Class I UGT Enzymes as a Novel Mechanism for Castration-Resistant Prostate Cancer A deficiency in class 1 UDP glucuronosyltransferase (UGT) enzymes was identified in prostate stem cells (SCs), which are involved in androgen catabolism. Class 1 UGT enzyme expression was also downregulated in cancer SCs and during progression to metastatic castration-resistant prostate cancer. [Brit J Cancer] Abstract CCR1/CCL5 Interaction Promotes Invasion of Taxane-Resistant PC3 Prostate Cancer Cells by Increasing Secretion of MMPs 2/9 and by Activating ERK and Rac Signaling Researchers investigated the role of the chemokine receptor 1 (CCR1) and its ligand, chemokine ligand 5 (CCL5), in taxane-resistant castration-refractory prostate cancer using paclitaxel-resistant prostate cancer cells established from PC3 cells. [Cytokine] Abstract Ghrelin O-acyltransferase (GOAT) Is Expressed in Prostate Cancer Tissues and Cell Lines and Expression Is Differentially Regulated In Vitro by Ghrelin Scientists demonstrated that GOAT mRNA and protein are expressed in the normal prostate and human prostate cancer tissue samples. The RWPE-1 and RWPE-2 normal prostate-derived cell lines and the LNCaP, DU145, and PC3 prostate cancer cell lines express GOAT and at least one other enzyme that is necessary to produce mature, acylated ghrelin from proghrelin. [Reprod Biol Endocrinol] Abstract Gene Signatures Distinguish Stage-Specific Prostate Cancer Stem Cells Isolated from Transgenic Adenocarcinoma of the Mouse Prostate Lesions and Predict the Malignancy of Human Tumors Researchers report the establishment of long-term self-renewing prostate cancer stem cells lines from the different stages of transgenic adenocarcinoma of the mouse prostate progression by application of the neurosphere assay. [Stem Cells Transl Med] Abstract Functional Activation of ATM by the Prostate Cancer Suppressor NKX3.1 NKX3.1 and ataxia telangiectasia mutated (ATM) have a functional interaction leading to ATM activation and then NKX3.1 degradation in a tightly regulated DNA damage response specific to prostate epithelial cells. [Cell Rep] Abstract | Graphical Abstract | Full Article CLINICAL RESEARCH Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer The authors assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. [N Engl J Med] Full Article | Press Release Vaccination of Castration-Resistant Prostate Cancer Patients with TroVax (MVA–5T4) in Combination with Docetaxel: A Randomized Phase II Trial Researchers report results from a randomized open-label Phase II trial in castration-resistant prostate cancer patients in which TroVax was administered in combination with docetaxel and compared against docetaxel alone. [Cancer Immunol Immunother] Abstract |